Supernus Pharmaceuticals (SUPN) Q3 2026 Earnings Call: Revenue Growth, Higher Guidance and Indivior Merger
Source Tradingkey
Key Takeaways
- Supernus Pharmaceuticals reported record Q3 2026 total revenue of $226.8 million, up 18% year over year, driven primarily by Qelbree, Gocovri, Zurzuvae and Onapco.
- GAAP operating earnings reached $21.2 million, compared with a $60.2 million operating loss in Q3 2025. Adjusted operating earnings increased to $55.2 million from $41.9 million.
- Combined revenue from the four growth products rose 43% year over year. Qelbree generated $91 million, Gocovri reached a record $43 million and Zurzuvae collaboration revenue totaled $41.7 million.
- Supernus raised its standalone 2026 revenue guidance to $875 million-$900 million and adjusted operating earnings guidance to $160 million-$180 million.
- Shareholders approved the Indivior Pharmaceuticals merger on October 15, and management expected the transaction to close on November 2. The company remains confident in achieving $125 million in expected annual cost synergies.
Core Financial Data
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Total revenue | $226.8 million | Up 18% year over year |
| Net product sales | $178.6 million | — |
| Zurzuvae collaboration revenue | $41.7 million | Approximately 50% of sales reported by Biogen |
| Royalties, licensing and other revenue | $6.5 million | — |
| Combined R&D and SG&A expenses | $153.8 million | $209.0 million in Q3 2025 |
| GAAP operating earnings | $21.2 million | Loss of $60.2 million in Q3 2025 |
| GAAP net earnings | $20.9 million | Loss of $45.1 million in Q3 2025 |
| Diluted EPS | $0.35 | Loss of $0.80 in Q3 2025 |
| Adjusted operating earnings | $55.2 million | $41.9 million in Q3 2025 |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Bank of America (BofA) expects gold below $4,000 over the next three months. The bank forecasts an average of $4,000 per ounce in the fourth quarter.Gold traded around $4,100 on Wednesday after hotter
Fed decision, US inflation and Middle East tensions take centre stage. Explore the US dollar, gold and AUD/USD outlook for Australian traders.
Alphabet (GOOGL) stock trades below its 200-day moving average by the widest margin in 17 months, Barchart data show. AI spending fears pushed shares near $317 ahead of Wednesday’s third-quarter (Q3)
Strategy, the former MicroStrategy and the largest corporate holder of Bitcoin (BTC), reported a record $21 billion operating profit for the third quarter on Thursday. Every dollar of it came from a p
Alphabet shares fell nearly 12% early Thursday, on track for their worst post-earnings drop on record. Google’s AI search is drawing more users but less ad money.The slide erased roughly $465 billion
